5-HT3 receptor antagonist (e.g., ondansetron): Standard antiemetic prophylaxis for chemotherapy-induced nausea and vomiting.
Acupoint application: Herbal plaster applied to selected acupoints to alleviate chemotherapy-induced nausea and vomiting.
Study summary
This single-center, randomized, controlled study evaluates whether acupoint application added to standard 5-HT3 receptor antagonist anti-nausea medication improves control of chemotherapy-induced nausea and vomiting in adults with lung cancer receiving first-line platinum-based chemotherapy. Participants will be randomly assigned to receive either acupoint application plus a 5-HT3 receptor antagonist or the 5-HT3 receptor antagonist alone for one chemotherapy cycle. The study will compare complete control of delayed nausea and vomiting between the two groups.
Eligibility
Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria:
* Pathologically or cytologically confirmed lung cancer.
* Scheduled to receive first-line platinum-based chemotherapy.
* Aged 18 to 75 years.
* Karnofsky Performance Status (KPS) score ≥ 60.
* Expected survival ≥ 3 months.
* Voluntarily signed written informed consent.
Exclusion Criteria:
* Known allergy to any component of the acupoint plaster.
* Severe skin disease, infection, or breakdown at the planned acupoint sites. --Pregnant or lactating women.
* Cognitive impairment or psychiatric disorder that prevents completion of study assessments.
* Participation in another interventional clinical trial within 30 days prior to enrollment.
Primary outcome measure(s)
Complete response rate of delayed-phase CINV (24-120 h) — 24 to 120 hours after the first cycle of platinum-based chemotherapy (each cycle is 21-28 days) Complete response is defined as no emetic episodes and no rescue antiemetic use during 24 to 120 hours after the first cycle of platinum-based chemotherapy. The outcome will be compared between the acupoint application plus 5-HT3 receptor antagonist group and the 5-HT3 receptor antagonist alone group.
Trial sites (1)
Facility
City
Region
Status
The Affiliated Yongchuan Hospital of Chongqing Medical University
Chongqing
Chongqing Municipality
Recruiting
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.